Le tofacitinib réduit l'inflammation spinale dans les corps vertébraux et les éléments postéro-latéraux dans la spondylarthrite ankylosante : Résultats d'un essai de phase 2
Rheumatol Ther. 2023;10(4):1001–1020 doi 10.1007/s40744-023-00564-y
Tofacitinib treatment is associated with a significant improvement in CANDEN MRI scores of spinal inflammation in axSpA patients. This study by Østergaard, et al. also validates the CANDEN MRI scoring system as an approach for measuring axSpA-associated inflammatory lesions.
The phase 2 multicentre, randomized, double-blind, placebo-controlled, dose-ranging trial had three treatment groups over the course of 12 Weeks: Tofacitinib 10 mg BID, tofacitinib 5 mg BID, and placebo. Both tofacitinib doses showed significant improvement in CANDEN scores, while showing an increased number of fat lesions observed using MRI.
Keywords:
